Feb 3, 2025 | Press Releases
Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – February 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...
Jan 22, 2025 | Press Releases
Registration Link for Presentation and live Q&A to take place, Wednesday January 29, 2025 at 2:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – January 22, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...
Jan 21, 2025 | Press Releases
Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activitiesMarlborough, Massachusetts–(Newsfile Corp. – January...
Jan 16, 2025 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – January 16, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...
Jan 15, 2025 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – January 15, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...
Jan 14, 2025 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – January 14, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...
